Bio-Rad Laboratories, Inc. Class A Common Stock vs J M Smucker Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.05 (market cap $9.43B), while J M Smucker Co trades at $118.74 (market cap $12.54B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.82% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SJM | |
|---|---|---|
Market Cap | $9.43B | $12.54B |
Sector | Health | Consumer Staples |
52-Week High | $356.25 | $126.35 |
52-Week Low | $241.71 | $89.53 |
Enterprise Value | $9.18B | $19.57B |
Dividend Yield | — | 3.82% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
SJM trades at $118.07, down 1.74% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported mixed fundamentals with strong revenue growth to $8.73B in 2025 but negative net income of -$1.23B. Recent dividend increases and positive earnings beats in Q4 2025 and Q1 2026 highlight management's confidence amid profitability challenges.
Wall Street maintains a cautiously optimistic outlook with 52% analyst buy ratings and a $125.11 consensus target, representing 6% upside. Key risks include persistent negative margins and high debt levels, while opportunities lie in cost controls and Uncrustables growth. The stock offers value at reasonable P/S and P/B multiples with dividend stability.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →